Microcirculation and Inflammatory Markers in Patients With Resistant, Stages 1/2 Hypertension and Normal Blood Pressure (MICRORAH)
29. april 2016 oppdatert av: Daniel Alexandre Bottino
Inflammatory Biomarkers and Endothelial Function Assessed by Venous Occlusion Plethysmography and Nailfold Videocapillaroscopy in Patients With Resistant Hypertension, Stages 1 and 2 and Normotensive
Nailfold videocapillaroscopy (NVC), Venous occlusion Plethysmography (VOP) and inflammatory biomarkers have been used to study endothelial function in patients with resistant hypertension, stages 1 and 2 hypertension and normotensive.
This was a cross-sectional study.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
Microcirculation determines peripheral resistance contributing to increased blood pressure.
The nailfold videocapillaroscopy (NVC), Venous occlusion Plethysmography (VOP) and biomarkers can be used to evaluate the microcirculation in arterial hypertension (AH).
The objective of this study is to analyze the behavior of serum inflammatory markers and study the microcirculation by nailfold videocapillaroscopy (NVC) and Venous Occlusion Plethysmography in patients with resistant hypertension (RH), with stages 1 and 2 hypertension (MMH ) and normotensive (CG).
A cross-sectional study with 75 patients has been performed: 25 with resistant hypertension (RH), 25 with stages 1 and 2 hypertension (MMH) and 25 normotensive (CG).
All underwent anamnesis, dosage serum markers and conducting NVC, VOP.
Hypertensive patients without statin use and with controlled or uncontrolled blood pressure were also analyzed.
For the statistical analysis were used: Kruskal -Wallis ANOVA, Dunn test and ANCOVA for correction of confusion factors such as age and BMI.
Studietype
Observasjonsmessig
Registrering (Faktiske)
75
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
27 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
First Day: Full clinical examination was performed, including measurements of at-rest blood pressure, weight and height in order to calculate Body Mass Index (BMI), waist and hip measurements.
Second Day: drawing blood for laboratory analyses, Nailfold Videocapillaroscopy and Venous Occlusion Plethysmography.
Beskrivelse
Inclusion Criteria:
- Clinical diagnosis of controlled High Blood Pressure stages 1 and 2 (blood pressure levels from 140/90 mmHg to 179/109 mmHg) .
- Resistant Hypertension (uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs).
- Normal Blood Pressure.
Exclusion Criteria:
- Diabetes Mellitus, Types 1 or 2.
- Heart Failure.
- Myocardial infarction or stroke with less than three months of the event.
- Chronic kidney disease.
- Use of hormonal or non-hormonal anti-inflammatory drugs.
- Recent trauma (less than three months).
- Autoimmune diseases.
- Infectious processes in activity.
- Neoplasia.
- Aspirin use (anti-inflammatory dose).
- Obesity grade III (Body Mass Index>40 kg/m2).
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Resistant Hypertension (RH)
uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.
|
|
Stages 1 and 2 Hypertension (MMH)
According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.
|
|
Normotensive (CG)
Blood Pressure <140/90 mmHg and without comorbidities.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood Pressure (mmHg)
Tidsramme: 1 day
|
Hemodynamic Variable
|
1 day
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Functional Capillary Density (FCD, number capillaries/mm2 )
Tidsramme: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Afferent Capillary Diameter (micrometer)
Tidsramme: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Apical Capillary Diameter (micrometer)
Tidsramme: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Efferent Capillary Diameter (micrometer)
Tidsramme: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Red Blood Cell Velocity (mm/s)
Tidsramme: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Maximum Red Blood Cell Velocity (mm/s)
Tidsramme: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Time to reach Maximum Red Blood Cell Velocity (s)
Tidsramme: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Waist circumference (cm)
Tidsramme: 1 day
|
Anthropometrical Variable
|
1 day
|
|
Hip circumference (cm)
Tidsramme: 1 day
|
Anthropometrical Variable
|
1 day
|
|
Waist to Hip Ratio
Tidsramme: 1 day
|
Anthropometrical Variable
|
1 day
|
|
Body Mass Index (Kg/m2)
Tidsramme: 1 day
|
Anthropometrical Variable
|
1 day
|
|
Maximal Forearm Blood Flow during reactive Hyperemia
Tidsramme: 1 day
|
Vascular Reactivity Variables from Venous Occlusion Plethysmography
|
1 day
|
|
Maximal Forearm Blood Flow after sublingual nitroglycerine
Tidsramme: 1 day
|
Vascular Reactivity Variables from Venous Occlusion Plethysmography
|
1 day
|
|
Vascular Cell Adhesion Molecule (VCAM, ng/dl)
Tidsramme: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
|
Intercellular Adhesion Molecule (ICAM, ng/dl)
Tidsramme: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
|
Adiponectin (ng/dl)
Tidsramme: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
|
Endothelin (pg/dl)
Tidsramme: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
|
C Reactive Protein (CRP, mg/dl)
Tidsramme: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2015
Primær fullføring (Faktiske)
1. desember 2015
Studiet fullført (Faktiske)
1. desember 2015
Datoer for studieregistrering
Først innsendt
20. april 2016
Først innsendt som oppfylte QC-kriteriene
29. april 2016
Først lagt ut (Anslag)
3. mai 2016
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
3. mai 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
29. april 2016
Sist bekreftet
1. april 2016
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RiodeJaneiro_StateUniversity
- BIOVASC-UERJ (Annen identifikator: Clinical and Experimental Research Lab on Vascular Biology)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .